These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 34209595)

  • 41. Clinical Outcome of Edoxaban vs. Vitamin K Antagonists in Patients with Atrial Fibrillation and Diabetes Mellitus: Results from a Multicenter, Propensity-Matched, Real-World Cohort Study.
    Russo V; Attena E; Rago A; Melillo E; Di Micco P; Papa AA; Napolitano G; D'Onofrio A; Golino P; Nigro G
    J Clin Med; 2020 May; 9(6):. PubMed ID: 32471222
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and safety of edoxaban compared with warfarin according to the burden of diseases in patients with atrial fibrillation: insights from the ENGAGE AF-TIMI 48 trial.
    Nicolau AM; Corbalan R; Nicolau JC; Ruff CT; Zierhut W; Kerschnitzki M; Duris T; Juul-Möller S; Voitk J; Trevisan M; Nordio F; Antman EM; Giugliano RP
    Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(3):167-175. PubMed ID: 31687762
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Postmarketing surveillance on clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA-AF-Japan): Three-month interim analysis results.
    Yamashita T; Koretsune Y; Ishikawa M; Shiosakai K; Kogure S
    J Arrhythm; 2019 Feb; 35(1):121-129. PubMed ID: 30805052
    [TBL] [Abstract][Full Text] [Related]  

  • 44. 'Real-world' management and outcomes of patients with paroxysmal vs. non-paroxysmal atrial fibrillation in Europe: the EURObservational Research Programme-Atrial Fibrillation (EORP-AF) General Pilot Registry.
    Boriani G; Laroche C; Diemberger I; Fantecchi E; Popescu MI; Rasmussen LH; Dan GA; Kalarus Z; Tavazzi L; Maggioni AP; Lip GY
    Europace; 2016 May; 18(5):648-57. PubMed ID: 26826133
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study.
    Olesen JB; Torp-Pedersen C; Hansen ML; Lip GY
    Thromb Haemost; 2012 Jun; 107(6):1172-9. PubMed ID: 22473219
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial.
    Boriani G; Ruff CT; Kuder JF; Shi M; Lanz HJ; Rutman H; Mercuri MF; Antman EM; Braunwald E; Giugliano RP
    Eur Heart J; 2019 May; 40(19):1541-1550. PubMed ID: 30624719
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study.
    Arihiro S; Todo K; Koga M; Furui E; Kinoshita N; Kimura K; Yamagami H; Terasaki T; Yoshimura S; Shiokawa Y; Kamiyama K; Takizawa S; Okuda S; Okada Y; Nagakane Y; Kameda T; Hasegawa Y; Shibuya S; Ito Y; Nakashima T; Takamatsu K; Nishiyama K; Matsuki T; Homma K; Takasugi J; Tokunaga K; Sato S; Kario K; Kitazono T; Toyoda K;
    Int J Stroke; 2016 Jul; 11(5):565-74. PubMed ID: 26927811
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Number needed to treat based on real-world evidence for non-vitamin K antagonist oral anticoagulants versus vitamin K antagonist oral anticoagulants in stroke prevention in patients with non-valvular atrial fibrillation.
    Briere JB; Bowrin K; Millier A; Toumi M; Wojciechowski P; Taieb V
    J Med Econ; 2019 Aug; 22(8):760-765. PubMed ID: 30969801
    [No Abstract]   [Full Text] [Related]  

  • 49. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial.
    Vranckx P; Valgimigli M; Eckardt L; Tijssen J; Lewalter T; Gargiulo G; Batushkin V; Campo G; Lysak Z; Vakaliuk I; Milewski K; Laeis P; Reimitz PE; Smolnik R; Zierhut W; Goette A
    Lancet; 2019 Oct; 394(10206):1335-1343. PubMed ID: 31492505
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight.
    Hohnloser SH; Fudim M; Alexander JH; Wojdyla DM; Ezekowitz JA; Hanna M; Atar D; Hijazi Z; Bahit MC; Al-Khatib SM; Lopez-Sendon JL; Wallentin L; Granger CB; Lopes RD
    Circulation; 2019 May; 139(20):2292-2300. PubMed ID: 30773022
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Anticoagulation Control in Warfarin-Treated Patients Undergoing Cardioversion of Atrial Fibrillation (from the Edoxaban Versus Enoxaparin-Warfarin in Patients Undergoing Cardioversion of Atrial Fibrillation Trial).
    Lip GYH; Al-Saady N; Jin J; Sun M; Melino M; Winters SM; Zamoryakhin D; Goette A
    Am J Cardiol; 2017 Sep; 120(5):792-796. PubMed ID: 28709650
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Stroke Risk Stratification Schemes in Atrial Fibrillation in the Era of Non- Vitamin K Anticoagulants: Misleading and Obsolete, At Least for the "Low-Risk" Patients?
    Manolis AS; Manolis TA; Manolis AA; Melita H
    Curr Drug Targets; 2017 Nov; 18(16):1852-1865. PubMed ID: 27593686
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Stroke prevention, 1-year clinical outcomes and healthcare resource utilization in patients with atrial fibrillation in France: Data from the GARFIELD-AF registry.
    Le Heuzey JY; Bassand JP; Berneau JB; Cozzolino P; D'Angiolella L; Doucet B; Mantovani LG; Martelet M; Mouallem J; Muller JJ; Pieper K;
    Arch Cardiovasc Dis; 2018 Dec; 111(12):749-757. PubMed ID: 29861295
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial.
    Hohnloser SH; Camm J; Cappato R; Diener HC; Heidbüchel H; Mont L; Morillo CA; Abozguia K; Grimaldi M; Rauer H; Reimitz PE; Smolnik R; Mönninghoff C; Kautzner J
    Eur Heart J; 2019 Sep; 40(36):3013-3021. PubMed ID: 30976787
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [ETNA-AF study: Italian baseline data and comparison with the European population in atrial fibrillation patients treated with edoxaban].
    Riva L; Diemberger I; Di Pasquale G; Attena E; Sangiuolo R; De Caterina R
    G Ital Cardiol (Rome); 2020 Feb; 21(2):141-151. PubMed ID: 32051638
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Is an Oral Anticoagulant Necessary for Young Atrial Fibrillation Patients With a CHA2DS2-VASc Score of 1 (Men) or 2 (Women)?
    Hung Y; Chao TF; Liu CJ; Tuan TC; Lin YJ; Chang SL; Lo LW; Hu YF; Liao JN; Chung FP; Lin WY; Lin WS; Cheng SM; Chen TJ; Lip GY; Chen SA
    J Am Heart Assoc; 2016 Oct; 5(10):. PubMed ID: 27702803
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial.
    Eisen A; Giugliano RP; Ruff CT; Nordio F; Gogia HS; Awasty VR; Henderson DA; Mercuri MF; Rutman H; Antman EM; Braunwald E
    Am Heart J; 2016 Feb; 172():144-51. PubMed ID: 26856226
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Decision-Making in Clinical Practice: Oral Anticoagulant Therapy in Patients with Non-valvular Atrial Fibrillation and a Single Additional Stroke Risk Factor.
    Potpara TS; Dagres N; Mujović N; Vasić D; Ašanin M; Nedeljkovic M; Marin F; Fauchier L; Blomstrom-Lundqvist C; Lip GY
    Adv Ther; 2017 Feb; 34(2):357-377. PubMed ID: 27933569
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of oral anticoagulation in patients with atrial fibrillation at very low thromboembolic risk.
    Verbrugge FH; Martin AC; Siegal D; Pieper K; Illingworth L; Camm AJ; Fox KAA
    Heart; 2020 Jun; 106(11):845-851. PubMed ID: 31806700
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Management of thromboembolic risk in patients with atrial fibrillation in Italy: baseline data from the PREFER in AF European Registry].
    De Caterina R; Renda G; Sangiuolo R; Attena E; Di Lecce L; Romeo F;
    G Ital Cardiol (Rome); 2014 Feb; 15(2):99-109. PubMed ID: 24625849
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.